• +55 (48) 3261-2856
  • contato@cienp.org.br

Category: Sem categoria

Upcoming market catalysts in Q1 2018

Potential market catalysts in the first quarter of 2018 include important top-line clinical trial results for rigerimod (developed by ImmuPharma and SymBio) for systemic lupus… Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018 …

NEWS & ANALYSIS

First in vivo gene-editing drugs enter the clinic Sangamo Therapeutics has started dosing patients with gene-editing drugs that are administered directly into the blood. Para acessar a publicação na íntegra clique aqui Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018…

FDA approves first digital pill

The FDA approved a first drug–device product that uses a digital chip to monitor ingestion. This tracking technology could help address the costly problem of poor drug adherence in both medical practice and clinical trials, if it lives up to its promise… Click here  to original publication. Fonte: 818 | DECEMBER 2017 | VOLUME 16…

Drugs that made headlines in 2017

In 2017, cancer drugs once again dominated the news, with many of these medications making headlines for being the first of their kind to gain approval. Beyond cancer, drugs for inflammatory diseases also received attention, for both their successes and their failures. Fonte: VOLUME 23 | NUMBER 12 | DECEMBER 2017 NATURE MEDICINE Click here to original publication.…

FDA approves ‘trackable’ pill

The Abilify MyCite aripiprazole tablets – for treating schizophrenia and manic episodes – have an ingestible sensor embedded inside them that records that the medication has been taken. Fonte: BBC NEWS Click here  to original publication.…

Spanish group defeats Shkreli in Chagas voucher race

The US Food and Drug Administration (FDA) approved for the first time a small-molecule drug to treat Chagas disease or American trypanosomiasis in children. The anti-parasitic benznidazole, has been around for over 40 years but until now it lacked an official go-ahead. Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 11 NOVEMBER 2017 Click here  to original publication.…

Predictable response

On 25 January 2015, Chih-Ming Ho, a former aerospace engineer, waited anxiously in his office at the University of California, Los Angeles, for an e-mail that would potentially alter the fate of a group of patients at the local liver-transplant center. Fonte: VOLUME 23 | NUMBER 11 | NOVEMBER 2017 NATURE MEDICINE Click here  to original publication.…

FDA approves antitoxin antibody

The FDA has approved Merck & Co’s bezlotoxumab to reduce the recurrence of Clostridium difficile infection, marking the first approval for a new approach to the treatment of bacterial infections. Unlike antibiotics, which kill pathogenic bacteria, bezlotoxumab is an antibody that mops up toxins that are released by C. difficile. Although antibiotics can control C. difficile, the infection recurs within weeks in around 25% of patients. In two phase III trials that tested bezlotoxumab in conjunction with standard of care…